Laura A. Sass

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 707 citations · Full text

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Histologic and ultrastructural features of the clara cell adenoma of the mouse lung.

Shirley L. Kauffman, Leslie Alexander, Laura A. Sass · PubMed · 1979 · 146 citations

Clara Cell Adenoma, Medicine, Pathology +5

Azithromycin for Early <i>Pseudomonas</i> Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial

Nicole Mayer-Hamblett, George Retsch‐Bogart, Margaret Kloster et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 96 citations · Full text

Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity

Pamela S. Hair, Laura A. Sass, Turaj Vazifedan et al. · PLoS ONE · 2017 · 32 citations · Full text

Inflammation, Acute Lung Injury, Complement System +15